NCT03179397

Brief Summary

To evaluate the Model SC9 Intraocular Lens for the improvement of near and intermediate vision when compared to a legally marketed monofocal IOL.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
338

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started May 2017

Longer than P75 for not_applicable

Geographic Reach
1 country

13 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 29, 2017

Completed
2 days until next milestone

Study Start

First participant enrolled

May 31, 2017

Completed
7 days until next milestone

First Posted

Study publicly available on registry

June 7, 2017

Completed
4.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 4, 2021

Completed
1.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 22, 2023

Completed
Last Updated

August 30, 2023

Status Verified

August 1, 2023

Enrollment Period

4.3 years

First QC Date

May 29, 2017

Last Update Submit

August 28, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Improvement in Visual Acuity Measurements using the LogMar Scale

    Subjects must read 20/40 or better, distance corrected near visual acuity and 20/40 or better distance corrected intermediate visual acuity. This is achieved with the subject wearing their best corrected spectacle correction in place and reading a series of letters at 40cm/16" and 80cm/32". Total letters read for each line will determine their visual acuity

    12 Months

Secondary Outcomes (1)

  • Defocus testing in 0.5D increments from -0.5 to -5.00D

    12 Months

Study Arms (2)

Model SC9

EXPERIMENTAL

Investigational IOL

Device: Model SC9

Model LI61SE

ACTIVE COMPARATOR

FDA Approved IOL

Device: Model LI61SE

Interventions

Model SC9DEVICE

Experimental

Model SC9

Active Comparator

Model LI61SE

Eligibility Criteria

Age22 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Twenty-two years or older at the time of surgery and diagnosed with bilateral cataracts
  • Able to comprehend and sign a statement of informed consent
  • Willing and able to complete all required postoperative visits
  • Calculated Lens Power within the available range for the study IOL's
  • Planned cataract removal by phacoemulsification
  • Potential postoperative visual acuity of BCDVA 0.2 LogMAR (20/32) or better in both eyes
  • Subjects with less than 1.0D of corneal astigmatism
  • Clear intraocular media other than cataract in the study eye
  • Preoperative BCDVA worse than 0.2 LogMar (20/32) with or without glare
  • Pupil size greater or equal to 6.0mm after dilation

You may not qualify if:

  • Any corneal abnormality, other than regular corneal astigmatism
  • Subjects with diagnosed degenerative visual disorders (e.g. macular degeneration or other retinal disorders) that are predicted to cause future acuity losses to a level worse than 0.2 LogMAR (20/32)
  • Previous refractive surgery
  • Amblyopia
  • Clinical severe corneal dystrophy (e.g., epithelial, stromal, or endothelial dystrophy)
  • Diabetic retinopathy
  • Extremely shallow anterior chamber, not due to swollen cataract
  • Microphthalmos
  • Previous retinal detachment
  • Previous corneal surgery
  • Recurrent severe anterior or posterior segment inflammation of unknown etiology
  • Rubella or traumatic cataract
  • Iris Neovascularization
  • Glaucoma (uncontrolled or controlled with medication)
  • Aniridia
  • +4 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (13)

Davies Eye Center

Carlsbad, California, 92008, United States

Location

Harvard Eye Associates

Laguna Hills, California, 92653, United States

Location

Coastal Vision Laser Eye Center

Orange, California, 92868, United States

Location

Shasta Eye Medical Group, Inc.

Redding, California, 96001, United States

Location

Aker-Kasten Eye Center

Boca Raton, Florida, 33432, United States

Location

The Eye Institute of West Florida

Largo, Florida, 33770, United States

Location

Chu Vision Institute

Bloomington, Minnesota, 55420, United States

Location

Silverstein Eye Centers

Kansas City, Missouri, 64133, United States

Location

Center for Sight

Las Vegas, Nevada, 89145, United States

Location

Fine, Hoffman and Sims

Eugene, Oregon, 97401, United States

Location

Houston Eye Associates

Houston, Texas, 77008, United States

Location

Parkhurst NuVision

San Antonio, Texas, 78229, United States

Location

Eye Associates of South Texas

San Antonio, Texas, 78247, United States

Location

MeSH Terms

Conditions

Cataract

Condition Hierarchy (Ancestors)

Lens DiseasesEye Diseases

Study Officials

  • John Hovanesian, M.D.

    CORD, LLC

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
Enrolled subjects will not be told which IOL they have received until the end of the study
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 29, 2017

First Posted

June 7, 2017

Study Start

May 31, 2017

Primary Completion

October 4, 2021

Study Completion

July 22, 2023

Last Updated

August 30, 2023

Record last verified: 2023-08

Data Sharing

IPD Sharing
Will not share

Locations